EGFR and non-small cell lung carcinoma: The research results of IMPRESS showed that there was no clinical benefit from the continuation of EGFR TKIs after the first-line EGFR TKIs resistant in advanced NSCLC patients with EGFR mutations, while in the subtypes with negative T790 M mutation, there was a tendency to benefit.[21] Because the residual lesion in the lung was too small to be punctured, we performed a liquid biopsy and the result showed no T790 M mutation.